ADMA Biologics Files Definitive Proxy Statement
Ticker: ADMA · Form: DEF 14A · Filed: Apr 15, 2025 · CIK: 1368514
| Field | Detail |
|---|---|
| Company | Adma Biologics, Inc. (ADMA) |
| Form Type | DEF 14A |
| Filed Date | Apr 15, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, shareholder-meeting
Related Tickers: ADMA
TL;DR
ADMA Biologics proxy statement is out - time to vote on directors & auditors.
AI Summary
ADMA Biologics, Inc. filed its definitive proxy statement (DEF 14A) on April 15, 2025, for its annual meeting of stockholders. The filing outlines the company's governance, executive compensation, and proposals to be voted on by shareholders, including the election of directors and ratification of its independent registered public accounting firm.
Why It Matters
This filing provides shareholders with crucial information to make informed voting decisions on company leadership and important corporate matters, impacting the company's strategic direction and governance.
Risk Assessment
Risk Level: low — This is a routine regulatory filing (DEF 14A) that provides information to shareholders and does not contain new material financial or operational news.
Key Players & Entities
- ADMA BIOLOGICS, INC. (company) — Registrant
- 0001140361-25-013967 (filing_id) — Accession Number
- 20250415 (date) — Filing Date
- 20250604 (date) — Period of Report
- R&R ACQUISITION VI, INC (company) — Former Company Name
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing is a definitive proxy statement required by the SEC for companies to solicit shareholder votes on important matters, such as the election of directors and ratification of auditors.
When was this DEF 14A filed by ADMA Biologics, Inc.?
ADMA Biologics, Inc. filed this DEF 14A on April 15, 2025.
What is the period of report for this filing?
The period of report for this DEF 14A filing is June 4, 2025.
What was ADMA Biologics, Inc.'s former company name?
ADMA Biologics, Inc.'s former company name was R&R ACQUISITION VI, INC.
What is the company's primary business according to the SIC code?
The company's primary business is Biological Products (No Diagnostic Substances), as indicated by SIC code 2836.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 15, 2025 regarding ADMA BIOLOGICS, INC. (ADMA).